Gland Pharma Seeks Shareholder Vote on Naina Lal Kidwai Reappointment and Pay

Gland Pharma's Board has approved the reappointment of Naina Lal Kidwai as an Independent Director for a second five-year term, beginning May 17, 2026. Shareholders will vote via postal ballot on her reappointment and proposed pay. This includes an annual sitting fee of ₹70 lakh for FY 2025-26 and a commission of 0.25% on net profits, capped at ₹100 lakh annually. The deadline for voting rights was April 10, 2026, with e-voting opening April 14, 2026.

Why Kidwai's Reappointment Matters

This reappointment signals Gland Pharma's focus on leadership stability and board continuity. Kidwai's deep experience in finance and governance is considered crucial for strategic direction and upholding high corporate standards. The proposed compensation is intended to reflect her expertise and contributions, with shareholder approval highlighting the company's commitment to investor involvement in key decisions.

Naina Lal Kidwai's Background

Naina Lal Kidwai joined Gland Pharma's board on May 17, 2021, for her initial term. Her career features prominent roles in finance, including Chairman of Rothschild & Co India and advisory roles with private equity firms. She is also a Padma Shri award recipient. Gland Pharma's shareholder-approved Nomination and Remuneration Policy guides director compensation, typically involving meeting fees and profit commissions aligned with company performance and regulations.

Shareholder Vote and Its Impact

If shareholders approve, Kidwai will continue to offer seasoned guidance. The voting process underscores shareholder democracy, giving investors a direct voice in board composition and director pay. This reappointment secures continued expertise, especially for navigating financial complexities and governance issues. The proposed pay structure now faces detailed review by the company's owners.

Potential Regulatory Hurdle

A key point is that Kidwai's proposed annual pay (commission plus fees) could exceed 50% of the total pay for all non-executive directors. If this happens, Gland Pharma will need a special resolution under SEBI Listing Regulations, which requires a higher level of shareholder approval.

Industry Practice: Director Compensation

Companies in India's pharmaceutical sector, such as Divi's Laboratories, Dr. Reddy's, Cipla, and Lupin, follow similar regulatory guidelines. Their independent director pay generally includes sitting fees and profit commissions, needing shareholder approval and adhering to regulatory limits. These models aim to attract experienced directors while ensuring crucial independence for corporate governance. Gland Pharma's proposal for Kidwai fits this industry norm.

What Investors Should Monitor

Investors will closely follow the postal ballot and e-voting results, due by May 15, 2026, which will confirm Kidwai's board continuation. Any requirement for a special resolution due to remuneration thresholds being met will be a key development. The success of shareholder approval will indicate investor confidence in the proposed governance move.